MAPT and Alzheimer disease: Multiple analytical platforms are used for measuring core CSF AD biomarkers; for example, INNOTEST (Fujirebio) provides clinically validated enzyme‐linked immunosorbent assays (ELISAs) for Aβ42, total‐tau (t‐tau), and phosphorylated‐tau at site 181 (p‐tau181).